[go: up one dir, main page]

PE20030867A1 - Derivados de quinazolinona - Google Patents

Derivados de quinazolinona

Info

Publication number
PE20030867A1
PE20030867A1 PE2003000129A PE2003000129A PE20030867A1 PE 20030867 A1 PE20030867 A1 PE 20030867A1 PE 2003000129 A PE2003000129 A PE 2003000129A PE 2003000129 A PE2003000129 A PE 2003000129A PE 20030867 A1 PE20030867 A1 PE 20030867A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
alkenyl
methyl
refers
Prior art date
Application number
PE2003000129A
Other languages
English (en)
Inventor
Christopher Thomas Brain
Edward Karol Dziadulewicz
Terance William Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20030867A1 publication Critical patent/PE20030867A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE QUINAZOLINA DE FORMULA I DONDE: R1, R2, R3, R4, R5 SON H, HALOGENO, ALQUILO, ALQUENILO, CICLOALQUILO, ALCOXILO-ALQUILO, HIDROXIALCOXILO, HIDROXILO, ENTRE OTROS; R1 Y R2 O R2 Y R3 JUNTO AL CARBONO FORMAN UN GRUPO CARBOCICLICO AROMATICO, ALIFATICO DE 5-10 MIEMBROS; R6 ES CH2-O-CO-NR12R13, CH2-X-CO-R14, ALQUILO, HIDROXIALQUILO; R7, R8, R9 SON ALQUILO; R10 Y R11 SON H, ALQUILO, ALQUENILO; CICLOALQUILO, ENTRE OTROS; R12 Y R13 SON H, ALQUILO, ALQUENILO, CICLOALQUILO, CICLOALQUILO-ALQUILO; R14 ES NH, ALQUILO-NH, ALQUENILO-NH, CICLOALQUILO-NH, CICLOALQUILO-ALQUILO-NH; X ES O, S; CUANDO R1 ES HALOGENO, METILO, ETILO, METOXILO, TRIFLUOROMETILO, H; R2, R3, R4 SON H, METILO, METOXILO; R5 ES H, METILO; R12 NO ES H, ALQUILO, ALQUENILO, ALQUILENO-SOR10. SON COMPUESTOS PREFERIDOS ETILESTER DEL ACIDO 2-ETILCARBAMOILOXIMETIL-5,7-DIMETIL-3-(2-METILSULFAMOIL-FENIL)-4-OXO-3,4-DIHIDRO-QUINAZOLIN-6-CARBOXILICO; ETILESTER DEL ACIDO 2-(2-HIDROXI-ETILCARBAMOILOXIMETIL)-5,7-DIMETIL-3-(2-METILSULFAMOIL-FENIL)-4-OXO-3,4-DIHIDRO-QUINAZOLIN-6-CARBOXILICO. TAMBIEN SE REFIERE A UN PROCESO PARA LA PRODUCCION. LOS COMPUESTOS SON AGONISTAS DEL RECEPTOR CANNABINOIDE Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DESORDENES OCULARES COMO GLAUCOMA, GLAUCOMA POR TENSION NORMAL, ENFERMEDADES NEURODEGENERATIVAS DE LA RETINA Y DEL NERVIO OPTICO. TAMBIEN SE REFIERE A UNA COMBINACION QUE EMPLEA ADEMAS UN FARMACO UTIL PARA EL DOLOR CRONICO, OSTEOARTRITIS, ARTRITIS REUMATOIDE, TENO-SINOVITIS, GOTA
PE2003000129A 2002-02-06 2003-02-04 Derivados de quinazolinona PE20030867A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound

Publications (1)

Publication Number Publication Date
PE20030867A1 true PE20030867A1 (es) 2003-12-04

Family

ID=27739227

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000129A PE20030867A1 (es) 2002-02-06 2003-02-04 Derivados de quinazolinona

Country Status (21)

Country Link
US (2) US20050085493A1 (es)
EP (2) EP2319839A1 (es)
JP (2) JP4428479B2 (es)
KR (1) KR100954626B1 (es)
CN (1) CN100579968C (es)
AR (1) AR038483A1 (es)
AT (1) ATE551329T1 (es)
AU (1) AU2003210212A1 (es)
BR (1) BR0307461A (es)
CA (1) CA2471974C (es)
CO (1) CO5601021A2 (es)
EC (1) ECSP045219A (es)
ES (1) ES2384967T3 (es)
MX (1) MXPA04007641A (es)
MY (1) MY143958A (es)
NO (1) NO328305B1 (es)
NZ (1) NZ571615A (es)
PE (1) PE20030867A1 (es)
PL (1) PL370657A1 (es)
TW (1) TW200306839A (es)
WO (1) WO2003066603A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4619545B2 (ja) 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ アミド誘導体
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
AU2004289638B2 (en) 2003-11-04 2009-10-01 Merck Sharp & Dohme Corp. Substituted naphthyridinone derivatives
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
AU2006268680B2 (en) * 2005-07-11 2012-11-22 Msd Oss B.V. Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (es) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
AU4246793A (en) * 1992-05-13 1993-12-13 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
WO1997029079A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN1628104A (zh) 2005-06-15
US20070265285A1 (en) 2007-11-15
CN100579968C (zh) 2010-01-13
KR100954626B1 (ko) 2010-04-27
ES2384967T3 (es) 2012-07-16
NO328305B1 (no) 2010-01-25
JP2009149658A (ja) 2009-07-09
JP4428479B2 (ja) 2010-03-10
WO2003066603A1 (en) 2003-08-14
TW200306839A (en) 2003-12-01
PL370657A1 (en) 2005-05-30
EP1472234A1 (en) 2004-11-03
BR0307461A (pt) 2004-11-09
KR20040083501A (ko) 2004-10-02
AU2003210212A1 (en) 2003-09-02
CO5601021A2 (es) 2006-01-31
EP2319839A1 (en) 2011-05-11
US20050085493A1 (en) 2005-04-21
ECSP045219A (es) 2004-09-28
HK1079518A1 (zh) 2006-04-07
ATE551329T1 (de) 2012-04-15
CA2471974A1 (en) 2003-08-14
MY143958A (en) 2011-07-29
NO20043580D0 (no) 2004-08-27
US8552015B2 (en) 2013-10-08
JP2005522439A (ja) 2005-07-28
CA2471974C (en) 2011-11-22
NZ571615A (en) 2010-01-29
AR038483A1 (es) 2005-01-19
MXPA04007641A (es) 2004-11-10
NO20043580L (no) 2004-09-21
EP1472234B1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
PE20030867A1 (es) Derivados de quinazolinona
PE20120418A1 (es) DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)
AU2010257272B2 (en) Compositions and methods for treating cognitive disorders
AR029626A1 (es) Derivados de acido carbamico, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
KR950701323A (ko) 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)
RU2008101923A (ru) Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора
AR031556A1 (es) Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden
RU2009147708A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
RU98114683A (ru) Производные 5-н-тиазол[3,2-a]пиримидина
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
KR930000490A (ko) 치료용 제제
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
IL299831B1 (en) Derivatives of substituted (isoxazolidine-2-yl)pyrimidine-4-yl-amino, and pharmaceutical composition comprising same as effective component
ATE509929T1 (de) Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
DE69214358D1 (de) Verbesserungen von oder in Bezug auf exzitatorische Aminosäurenrezeptorantagonisten
UY25095A1 (es) Derivados de la 5h-tiazolo (3,2-a) pirimidina
RU2009136592A (ru) Терапевтические агенты
AR035945A1 (es) Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones
PE20030714A1 (es) Derivados de amidas de acido antranilico como inhibidores del receptor de tirosina quinasa vegf
EA202190431A1 (ru) Гетероароматические модуляторы nmda рецептора и их применение
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
AR055059A1 (es) Antagonistas y agonistas de piperazin-piperidina del receptor 5ht1a

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed